GCP
FHTX icon

GSA Capital Partners’s Foghorn Therapeutics FHTX Stock Holding History

GSA Capital Partners’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144K Buy
+29,506
New +$131K 0.01% 1587
2024
Q2 		– Sell
-21,855
Closed -$147K – 1751
2024
Q1 		$147K Sell
21,855
-19,440
-47% -$108K 0.01% 1450
2023
Q4 		$266K Buy
+41,295
New +$178K 0.02% 1178

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

GSA Capital Partners's FHTX Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Foghorn Therapeutics (FHTX) in Q2 2026: 29,506 shares worth $144K. The stake represents 0.01% of the portfolio and ranks #1587 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in FHTX as recently as Q1 2024.

GSA Capital Partners first reported a position in FHTX in Q4 2023 and has held it in 3 quarters since. The position peaked at $266K in Q4 2023. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • GSA Capital Partners held 29,506 shares of Foghorn Therapeutics worth $144K as of Q2 2026.
  • Foghorn Therapeutics was a new GSA Capital Partners position in Q2 2026.
  • Foghorn Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1587 holding.
  • GSA Capital Partners first reported a position in Foghorn Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • GSA Capital Partners's Foghorn Therapeutics position peaked at $266K in Q4 2023.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.